Origins of the Hexahydroquinoline Scaffold: The Antaki Three-Component Reaction (1963)
Hexahydroquinolines are a class of partially saturated quinoline derivatives. In the most-studied form, the carbocyclic ring is fully reduced while the nitrogen-containing ring retains a 1,4-dihydropyridine core — the same pharmacophore found in nifedipine and the broader family of calcium channel blocker drugs [2].
A Note on Terminology: "HHQ" Is Not One Thing
Before going further, it's worth clearing up a point of genuine confusion in the literature. The term "hexahydroquinoline" (HHQ) is used in at least two different ways that don't always overlap.
First, the name itself is structurally ambiguous. The dominant meaning — and the one this article is about — is the 1,4,5,6,7,8-hexahydroquinoline form, in which the carbocyclic ring is fully saturated and the nitrogen-containing ring retains the dihydropyridine (enamine) double bond [1]. A less common 1,2,3,4,4a,5-hexahydroquinoline form exists with the saturation pattern distributed differently, and no dihydropyridine unit at all [1]. The two are not interchangeable, even though both are technically "hexahydroquinolines."
Second, and more consequential for tracing the history of this chemistry: the 1,4,5,6,7,8-hexahydroquinoline core is very often the same molecule that a separate, much larger body of literature calls a polyhydroquinoline (PHQ). A 2026 study, for instance, describes "the polyhydroquinoline derivative 4-(4-hydroxy-phenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid ethyl ester" [11] — using both names for the identical compound in the same sentence. The modern green-chemistry and catalysis literature on multi-component synthesis overwhelmingly favors "polyhydroquinoline," while medicinal chemistry, crystallography, and older sources favor "hexahydroquinoline." They are, in the case of the 1,4,5,6,7,8-form, generally the same scaffold under two different names — which means a literature search under one term can easily miss decades of relevant work filed under the other.
With that distinction in hand, the classical routes to this scaffold are worth tracing precisely, because the shorthand "Hantzsch synthesis of hexahydroquinolines" — common in both literatures — carries assumptions that don't hold up against the original reports.
The 1882 Starting Point — and Its Limitations
Arthur Hantzsch's original 1882 pyridine synthesis produces simple, unfused 1,4-dihydropyridines from an aldehyde, ammonia, and a β-ketoester [3]. It does not generate a bicyclic hexahydroquinoline system — there is no second ring. This is worth checking directly, because a 1965 paper is sometimes cited alongside Hantzsch's name as part of the classical foundation for hexahydroquinoline synthesis [5]; the original text doesn't support that framing. Loev and Snader's study of the oxidative dealkylation of Hantzsch dihydropyridines uses exactly this simple, non-fused system, prepared from an aldehyde, ammonia, and ethyl acetoacetate or aminocrotononitrile [4]. No cyclic diketone, no fused ring, no connection to the hexahydroquinoline scaffold.
An earlier extension did exist: Knoevenagel and Ruschhaupt applied Hantzsch-type chemistry to cyclic 1,3-diketones as far back as 1898 [6]. But reacting a cyclic diketone with an aldehyde alone, without a nitrogen-bearing partner, gives only a symmetric bis-condensation adduct — two diketone units bridged by the aldehyde carbon, with no nitrogen heterocycle at all [7].
1963 — Emergence of the Fused Scaffold: The Antaki Reaction
The first successful preparation of the fused 4-aryl hexahydroquinoline system was reported by H. Antaki in 1963, working at the Research Institute for Tropical Medicine in Cairo [7]. The reaction is a three-component condensation of cyclohexane-1,3-dione, an aromatic aldehyde, and ethyl β-aminocrotonate in ethanol and glacial acetic acid under reflux for one hour.
The paper notes that the few existing routes to related tetrahydroquinolines "were not adaptable for preparation of these derivatives" [7] — the fused, 4-aryl hexahydroquinoline was, at the time, an unsolved structural problem rather than a routine extension of known chemistry.
Figure 1. The Antaki Three-Component Synthesis (1963)
!["Antaki]("figure1_antaki_scheme.png")
Figure 1. Schematic of the Antaki three-component synthesis (1963). Cyclohexane-1,3-dione, an aromatic aldehyde (Ar-CHO), and ethyl β-aminocrotonate react in ethanol/glacial acetic acid under reflux for one hour to yield the hexahydroquinoline ester (I). Further oxidative dehydrogenation with chromium trioxide (CrO3/AcOH) gives the tetrahydroquinoline (II). No metal catalysts or inert atmosphere required.
Original Reaction Conditions (1963)
| Parameter | Detail |
|---|---|
| Reactants | Cyclohexane-1,3-dione · Aromatic aldehyde · Ethyl β-aminocrotonate |
| Solvent | Ethanol and glacial acetic acid |
| Temperature | Reflux |
| Reaction time | 1 hour |
| Workup | Product crystallises directly from the reaction mixture |
| Catalyst | None — no transition metal catalysts required |
| Atmosphere | Ambient — no inert atmosphere required |
| Aryl substituents reported | p-nitrophenyl, p-methoxyphenyl, 3,4-dimethoxyphenyl, p-dimethylaminophenyl, p-chlorophenyl, o-nitrophenyl |
| Oxidation step | Chromium trioxide in dilute acetic acid — converts hexahydroquinolines to tetrahydroquinolines |
The same 1963 paper maps out what happens with each combination of starting materials, and the three outcomes are worth setting out plainly [7]:
- Diketone + aromatic aldehyde + ethyl β-aminocrotonate → hexahydroquinoline. The reaction that works — nitrogen enters as a pre-formed enamine.
- Diketone + aromatic aldehyde + ammonium acetate → dioxoacridine. Swap the enamine for free ammonia and the reaction runs to a symmetric, three-ring acridine instead — a different product entirely, using the same diketone and aldehyde.
- Diketone + aromatic aldehyde alone → bis-condensation adduct. With no nitrogen source at all, the two components simply bridge into a symmetric adduct — no heterocycle forms.
That comparison pins down what actually mattered: not the diketone, not the aldehyde, but the specific choice to introduce nitrogen as a pre-formed enamine rather than as free ammonia. Only that combination gives the asymmetric, fused hexahydroquinoline ring. This 1963 report is the earliest verified synthesis of the target bicyclic scaffold found in the record to date.
1975 — A Closely Related Variant (Stankevich et al.)
Stankevich and co-workers later described a related route using dimedone and paraformaldehyde, producing 4-unsubstituted hexahydroquinolines [1]. Both reactions give 4-substituted hexahydroquinolines as a class — the same heterocyclic core. The difference is positional: Antaki's aromatic aldehyde places an aryl group at the C-4 position, while Stankevich's paraformaldehyde leaves that position unsubstituted [1]. Recent reviews frame the 1975 work as a related study following a similar reaction to the 1963 method [1].
Broader Context and Therapeutic Relevance
Bossert and Vater — the chemists credited with developing nifedipine — cited Antaki's 1963 work twice in their 1989 review of dihydropyridine calcium antagonists, placing it in direct synthetic lineage alongside Knoevenagel's 1898 work as part of the background to this drug class [8]. A 2026 review in Frontiers in Chemistry formally referred to the method as the Antaki reaction — apparently the first peer-reviewed use of that eponym [1].
Hexahydroquinoline (and, under the other name, polyhydroquinoline) derivatives have since demonstrated diverse biological activities, including antimalarial and transmission-blocking effects [9], calcium channel modulation [2], anticancer activity including EGFR inhibition [10], and antimicrobial, antioxidant, and anti-inflammatory properties [1]. Antaki’s 1963 paper frames the compounds in synthetic terms — as intermediates on the way to other derivatives — rather than as candidate drugs, but that reflects the stated purpose of that particular paper, not a lack of awareness of biological relevance. Antaki worked at Cairo’s Research Institute for Tropical Medicine, an institute organized around disease, principally malaria and bilharzia. What his institute lacked in 1963 wasn’t insight into which molecules might matter biologically — it was the screening infrastructure, decades before large-scale pharmaceutical testing existed as it does now, to test a new scaffold against a wide panel of biological targets. That infrastructure came later, and applied to this exact scaffold, it found real activity across several of the same disease areas his institute already worked on.
www.hekmatantaki.orgReferences
[1] Oduselu, G. O. et al. "Emerging insights into chemistry and therapeutic potentials of functionalized hexahydroquinolines." Frontiers in Chemistry 14 (2026): 1769586. https://doi.org/10.3389/fchem.2026.1769586
[2] Petreni, A. et al. "Focusing on C-4 position of Hantzsch 1,4-dihydropyridines." European Journal of Medicinal Chemistry (2022). https://doi.org/10.1016/j.ejmech.2022.114810
[3] Hantzsch, A. Justus Liebigs Annalen der Chemie 215 (1882): 1.
[4] Loev, B.; Snader, K. M. "The Hantzsch Reaction. I. Oxidative Dealkylation of Certain Dihydropyridines." Journal of Organic Chemistry 30 (1965): 1914–1916. https://doi.org/10.1021/jo01017a048
[5] Mansoor, S. S. et al. "An efficient one-pot multi-component synthesis of polyhydroquinoline derivatives through Hantzsch reaction catalysed by Gadolinium triflate." Arabian Journal of Chemistry (2017).
[6] Knoevenagel, E.; Ruschhaupt, W. Berichte der deutschen chemischen Gesellschaft 31 (1898): 1025.
[7] Antaki, H. "The Synthesis of Ethyl 4-Aryl-5,6,7,8-tetrahydro-5-oxoquinoline-3-carboxylates and their Derivatives." Journal of the Chemical Society (Resumed) (1963): 4877–4879. https://doi.org/10.1039/jr9630004877
[8] Bossert, F.; Vater, W. "Dihydropyridines — a class of clinically important calcium channel blockers." Medicinal Research Reviews 9 (1989). https://doi.org/10.1002/med.2610090304
[9] Vanaerschot, M. et al. "Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity." Nature Microbiology 2, no. 10 (2017): 1403–1414. https://doi.org/10.1038/s41564-017-0007-4
[10] Abo Al-Hamd, M. G. et al. "Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR." Journal of Enzyme Inhibition and Medicinal Chemistry 38, no. 1 (2023): 2241674. https://doi.org/10.1080/14756366.2023.2241674
[11] "Enzyme modulation and antimicrobial activity of the polyhydroquinoline derivative 4-(4-hydroxy-phenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid ethyl ester." Revista Brasileira Multidisciplinar 29, no. 1 (2026): 171–186. https://doi.org/10.25061/2527-2675/ReBraM/2026.v29i1.2289
